235 related articles for article (PubMed ID: 35140265)
21. Molecular docking studies, molecular dynamics and ADME/tox reveal therapeutic potentials of STOCK1N-69160 against papain-like protease of SARS-CoV-2.
Elekofehinti OO; Iwaloye O; Josiah SS; Lawal AO; Akinjiyan MO; Ariyo EO
Mol Divers; 2021 Aug; 25(3):1761-1773. PubMed ID: 33201386
[TBL] [Abstract][Full Text] [Related]
22. Structure-Based Screening to Discover New Inhibitors for Papain-like Proteinase of SARS-CoV-2: An
Jamalan M; Barzegari E; Gholami-Borujeni F
J Proteome Res; 2021 Jan; 20(1):1015-1026. PubMed ID: 33350309
[TBL] [Abstract][Full Text] [Related]
23. Inhibitory effect of phytochemicals towards SARS-CoV-2 papain like protease (PLpro) proteolytic and deubiquitinase activity.
Kawall A; Lewis DSM; Sharma A; Chavada K; Deshmukh R; Rayalam S; Mody V; Taval S
Front Chem; 2022; 10():1100460. PubMed ID: 36712981
[TBL] [Abstract][Full Text] [Related]
24. Inhibitors of Deubiquitinating Enzymes Interfere with the SARS-CoV-2 Papain-like Protease and Block Virus Replication In Vitro.
Große M; Setz C; Rauch P; Auth J; Morokutti-Kurz M; Temchura V; Schubert U
Viruses; 2022 Jun; 14(7):. PubMed ID: 35891385
[TBL] [Abstract][Full Text] [Related]
25. Identification of potent food constituents as SARS-CoV-2 papain-like protease modulators through advanced pharmacoinformatics approaches.
Bhowmick S; Saha A; AlFaris NA; ALTamimi JZ; ALOthman ZA; Aldayel TS; Wabaidur SM; Islam MA
J Mol Graph Model; 2022 Mar; 111():108113. PubMed ID: 34959151
[TBL] [Abstract][Full Text] [Related]
26. SARS-CoV-2 Papain-Like Protease Potential Inhibitors-In Silico Quantitative Assessment.
Stasiulewicz A; Maksymiuk AW; Nguyen ML; Bełza B; Sulkowska JI
Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33921228
[TBL] [Abstract][Full Text] [Related]
27. High-throughput screening identifies established drugs as SARS-CoV-2 PLpro inhibitors.
Zhao Y; Du X; Duan Y; Pan X; Sun Y; You T; Han L; Jin Z; Shang W; Yu J; Guo H; Liu Q; Wu Y; Peng C; Wang J; Zhu C; Yang X; Yang K; Lei Y; Guddat LW; Xu W; Xiao G; Sun L; Zhang L; Rao Z; Yang H
Protein Cell; 2021 Nov; 12(11):877-888. PubMed ID: 33864621
[TBL] [Abstract][Full Text] [Related]
28. Parthenolide reveals an allosteric mode to inhibit the deISGylation activity of SARS-CoV‑2 papain-like protease.
Zou Z; Shan H; Sun D; Xia L; Shi Y; Wan J; Zhou A; Wu Y; Xu H; Lei H; Xu Z; Wu Y
Acta Biochim Biophys Sin (Shanghai); 2022 Aug; 54(8):1133-1139. PubMed ID: 35866602
[TBL] [Abstract][Full Text] [Related]
29. The SARS-CoV-2 papain-like protease suppresses type I interferon responses by deubiquitinating STING.
Cao D; Duan L; Huang B; Xiong Y; Zhang G; Huang H
Sci Signal; 2023 May; 16(783):eadd0082. PubMed ID: 37130168
[TBL] [Abstract][Full Text] [Related]
30. Proteolytic processing, deubiquitinase and interferon antagonist activities of Middle East respiratory syndrome coronavirus papain-like protease.
Yang X; Chen X; Bian G; Tu J; Xing Y; Wang Y; Chen Z
J Gen Virol; 2014 Mar; 95(Pt 3):614-626. PubMed ID: 24362959
[TBL] [Abstract][Full Text] [Related]
31. Development of potent and selective inhibitors targeting the papain-like protease of SARS-CoV-2.
Shan H; Liu J; Shen J; Dai J; Xu G; Lu K; Han C; Wang Y; Xu X; Tong Y; Xiang H; Ai Z; Zhuang G; Hu J; Zhang Z; Li Y; Pan L; Tan L
Cell Chem Biol; 2021 Jun; 28(6):855-865.e9. PubMed ID: 33979649
[TBL] [Abstract][Full Text] [Related]
32. The emerging SARS-CoV-2 papain-like protease: Its relationship with recent coronavirus epidemics.
Kandeel M; Kitade Y; Fayez M; Venugopala KN; Ibrahim A
J Med Virol; 2021 Mar; 93(3):1581-1588. PubMed ID: 32902889
[TBL] [Abstract][Full Text] [Related]
33. A computational essential dynamics approach to investigate structural influences of ligand binding on Papain like protease from SARS-CoV-2.
Singh E; Jha RK; Khan RJ; Kumar A; Jain M; Muthukumaran J; Singh AK
Comput Biol Chem; 2022 Aug; 99():107721. PubMed ID: 35835027
[TBL] [Abstract][Full Text] [Related]
34. Interactions between SARS coronavirus 2 papain-like protease and immune system: A potential drug target for the treatment of COVID-19.
Mahmoudvand S; Shokri S
Scand J Immunol; 2021 Oct; 94(4):e13044. PubMed ID: 33872387
[TBL] [Abstract][Full Text] [Related]
35. Zinc
Panchariya L; Khan WA; Kuila S; Sonkar K; Sahoo S; Ghoshal A; Kumar A; Verma DK; Hasan A; Khan MA; Jain N; Mohapatra AK; Das S; Thakur JK; Maiti S; Nanda RK; Halder R; Sunil S; Arockiasamy A
Chem Commun (Camb); 2021 Sep; 57(78):10083-10086. PubMed ID: 34514483
[TBL] [Abstract][Full Text] [Related]
36. Design and Evaluation of a Novel Peptide-Drug Conjugate Covalently Targeting SARS-CoV-2 Papain-like Protease.
Liu N; Zhang Y; Lei Y; Wang R; Zhan M; Liu J; An Y; Zhou Y; Zhan J; Yin F; Li Z
J Med Chem; 2022 Jan; 65(1):876-884. PubMed ID: 34981929
[TBL] [Abstract][Full Text] [Related]
37. Indole Chloropyridinyl Ester-Derived SARS-CoV-2 3CLpro Inhibitors: Enzyme Inhibition, Antiviral Efficacy, Structure-Activity Relationship, and X-ray Structural Studies.
Ghosh AK; Raghavaiah J; Shahabi D; Yadav M; Anson BJ; Lendy EK; Hattori SI; Higashi-Kuwata N; Mitsuya H; Mesecar AD
J Med Chem; 2021 Oct; 64(19):14702-14714. PubMed ID: 34528437
[TBL] [Abstract][Full Text] [Related]
38. A chimeric virus-mouse model system for evaluating the function and inhibition of papain-like proteases of emerging coronaviruses.
Deng X; Agnihothram S; Mielech AM; Nichols DB; Wilson MW; StJohn SE; Larsen SD; Mesecar AD; Lenschow DJ; Baric RS; Baker SC
J Virol; 2014 Oct; 88(20):11825-33. PubMed ID: 25100850
[TBL] [Abstract][Full Text] [Related]
39. Aurasperone A Inhibits SARS CoV-2 In Vitro: An Integrated In Vitro and In Silico Study.
ElNaggar MH; Abdelwahab GM; Kutkat O; GabAllah M; Ali MA; El-Metwally MEA; Sayed AM; Abdelmohsen UR; Khalil AT
Mar Drugs; 2022 Feb; 20(3):. PubMed ID: 35323478
[TBL] [Abstract][Full Text] [Related]
40. Protease targeted COVID-19 drug discovery: What we have learned from the past SARS-CoV inhibitors?
Amin SA; Banerjee S; Gayen S; Jha T
Eur J Med Chem; 2021 Apr; 215():113294. PubMed ID: 33618158
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
